About Apricus Biosciences (NASDAQ:APRI)
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APRI
CUSIPN/A
Phone858-222-8041
Debt
Debt-to-Equity RatioN/A
Current Ratio4.17%
Quick Ratio4.17%
Price-To-Earnings
Trailing P/E Ratio-0.26
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.76 million
Price / Sales1.06
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book0.90
Profitability
EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-200.61%
Return on Assets-142.23%
Miscellaneous
Employees11
Outstanding Shares23,440,000
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences (NASDAQ:APRI) released its earnings results on Thursday, March, 1st. The company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. During the same period in the prior year, the company posted $0.03 earnings per share. View Apricus Biosciences' Earnings History.
When is Apricus Biosciences' next earnings date?
What price target have analysts set for APRI?
2 equities research analysts have issued 1 year price targets for Apricus Biosciences' stock. Their predictions range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' share price to reach $1.00 in the next year. View Analyst Ratings for Apricus Biosciences.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include RXi Pharmaceuticals (RXII), Onconova Therapeutics (ONTX), EpiCept (IMNP), Acura Pharmaceuticals (ACUR), Dare Bioscience (DARE), EyeGate Pharma (EYEG), Auris Medical (EARS), Anthera Pharmaceuticals (ANTH), Bioblast Pharma (ORPN), Heat Biologics (HTBX), Cotinga Pharmaceuticals (COTQF), Orexigen Therapeutics (OREX), Argos Therapeutics (ARGS), Rosetta Genomics (ROSG), Affymax (AFFY), TetraLogic (TLOG) and Patheon (PTHN).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, Chief Exec. Officer, Principal Accounting Officer, Sec. and Director (Age 54)
- Mr. Brian T. Dorsey, Chief Devel. Officer and Sr. VP (Age 49)
- Mr. Neil C. Morton, Chief Bus. Officer and Sr. VP (Age 42)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP and Gen. Counsel
Has Apricus Biosciences been receiving favorable news coverage?
Press coverage about APRI stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Apricus Biosciences earned a media sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the company an impact score of 47.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Apricus Biosciences' major shareholders?
How do I buy shares of Apricus Biosciences?
Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
One share of APRI stock can currently be purchased for approximately $0.2596.
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $6.09 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Apricus Biosciences (NASDAQ:APRI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Apricus Biosciences in the last 12 months. Their average twelve-month price target is $1.00, suggesting that the stock has a possible upside of 285.21%. The high price target for APRI is $1.00 and the low price target for APRI is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.00 | $1.00 | $5.00 | $4.50 |
| Price Target Upside: | 285.21% upside | 68.65% downside | 79.86% upside | 188.46% upside |
Apricus Biosciences (NASDAQ:APRI) Consensus Price Target History
Apricus Biosciences (NASDAQ:APRI) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Apricus Biosciences (NASDAQ:APRI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Apricus Biosciences (NASDAQ APRI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.32%
Institutional Ownership Percentage: 12.96%
Apricus Biosciences (NASDAQ APRI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/31/2017 | Alexander J Denner | Major Shareholder | Buy | 6,104 | $1.63 | $9,949.52 | |  |
| 3/3/2016 | Alexander J Denner | Major Shareholder | Buy | 6,647,728 | $0.88 | $5,850,000.64 | | |
| 1/12/2016 | Alexander J Denner | Major Shareholder | Buy | 1,306,819 | $0.88 | $1,150,000.72 | | |
| 12/29/2014 | Brian Dorsey | Insider | Buy | 10,000 | $1.05 | $10,500.00 | | |
| 12/22/2014 | Richard W Pascoe | CEO | Buy | 10,000 | $1.02 | $10,200.00 | | |
| 10/23/2014 | Sandford D Smith | Director | Buy | 26,500 | $1.57 | $41,605.00 | | |
| 1/3/2014 | Leonard A Oppenheim | Director | Sell | 15,212 | $2.49 | $37,877.88 | | |
| 12/26/2013 | Kleanthis G Xanthopoulos | Director | Sell | 17,184 | $2.55 | $43,819.20 | | |
| 6/21/2013 | Kleanthis G Xanthopoulos | Director | Sell | 2,864 | $2.52 | $7,217.28 | | |
| 5/23/2013 | Richard W Pascoe | CEO | Buy | 35,000 | $2.85 | $99,750.00 | | |
| 5/23/2013 | Rusty Ray | Director | Buy | 5,000 | $2.85 | $14,250.00 | | |
| 5/23/2013 | Steven Robert Martin | CFO | Buy | 20,000 | $2.85 | $57,000.00 | | |
| 5/21/2013 | Kleanthis G Xanthopoulos | Director | Sell | 2,864 | $3.36 | $9,623.04 | | |
| 8/20/2012 | Edward M Cox | VP | Buy | 1,500 | $2.73 | $4,095.00 | | |
| 8/17/2012 | Rusty Ray | Director | Buy | 4,000 | $2.81 | $11,240.00 | | |
(Data available from 1/1/2013 forward)
Apricus Biosciences (NASDAQ APRI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Apricus Biosciences (APRI) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 18 at 1:14 AM |
 | Apricus Begins Discussions With Interested Parties For U.S. Vitaros Rights
www.nasdaq.com - April 17 at 5:31 PM |
 | Apricus Bio has work to do before refiling U.S. marketing application for ED cream Vitaros; shares down 10% premarket
seekingalpha.com - April 16 at 5:28 PM |
 | BRIEF-Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter
www.reuters.com - April 16 at 5:28 PM |
| UPDATE 1-Apricus mulling strategic options after FDA meeting
www.reuters.com - April 16 at 9:15 AM |
| BRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDA
www.reuters.com - April 16 at 9:15 AM |
 | FDA asks for new formulation of Apricus' erectile dysfunction cream
finance.yahoo.com - April 16 at 9:15 AM |
| Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
finance.yahoo.com - April 16 at 9:15 AM |
| Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
finance.yahoo.com - April 16 at 9:15 AM |
| Apricus mulls options; to sell U.S. rights to Vitaros
finance.yahoo.com - April 16 at 9:15 AM |
| HC Wainwright Analysts Give Apricus Biosciences (APRI) a $4.00 Price Target
www.americanbankingnews.com - April 13 at 7:13 PM |
| Apricus Biosciences (APRI) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 9 at 12:44 PM |
| Apricus Bio closes stock offering
seekingalpha.com - April 5 at 9:38 AM |
| Apricus Biosciences Announces Closing of $3.55 Million Public Offering
finance.yahoo.com - April 4 at 4:35 PM |
 | Global Erectile Dysfunction Market Opportunities 2018: Bayer AG, K. Chemicals, Cristalia Produtos Quimicos Farmaceuticos, Apricus Biosciences
www.marketwatch.com - April 3 at 8:21 AM |
| -$0.10 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter
www.americanbankingnews.com - April 1 at 1:21 AM |
| BRIEF-Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus Biosciences
www.reuters.com - March 29 at 5:16 PM |
| BRIEF-Apricus Biosciences Announces Pricing Of $3.55 Mln Public Offering
www.reuters.com - March 29 at 8:24 AM |
| Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why
finance.yahoo.com - March 29 at 8:24 AM |
 | Apricus Biosciences (APRI) Prices $3.55 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - March 28 at 5:20 PM |
| Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
finance.yahoo.com - March 28 at 5:20 PM |
| Apricus Biosciences (APRI) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 28 at 2:06 PM |
| Apricus Biosciences (APRI) Commences Public Offering of Common Stock, Warrants
www.streetinsider.com - March 28 at 8:02 AM |
| BRIEF-Apricus Biosciences Files For Offering Of 7.1 Mln Units
www.reuters.com - March 28 at 8:02 AM |
 | Apricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public Offering
www.finanznachrichten.de - March 27 at 5:31 PM |
| Apricus Biosciences Announces Proposed Public Offering
finance.yahoo.com - March 27 at 5:31 PM |
| Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
finance.yahoo.com - March 26 at 9:12 AM |
| Apricus Biosciences (APRI) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM |
| BRIEF-Sarissa Capital Management Entered Into Warrant Amendment Agreement With Apricus Biosciences
www.reuters.com - March 24 at 5:34 PM |
| Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash
finance.yahoo.com - March 22 at 8:26 AM |
| Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline
finance.yahoo.com - March 22 at 8:26 AM |
| Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:48 AM |
| Apricus Biosciences Inc (APRI) Short Interest Up 115.4% in February
www.americanbankingnews.com - March 3 at 1:52 AM |
| Apricus Biosciences (APRI) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 2 at 11:56 AM |
| At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?
finance.yahoo.com - March 1 at 5:28 PM |
| Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:28 PM |
| Apricus Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 5:28 PM |
| Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:28 PM |
| Zacks: Analysts Expect Apricus Biosciences Inc (APRI) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - February 25 at 11:08 PM |
| Apricus Biosciences (APRI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 22 at 8:16 PM |
| Zacks Investment Research Lowers Apricus Biosciences (APRI) to Sell
www.americanbankingnews.com - February 22 at 4:32 PM |
 | Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:23 AM |
| Contrasting Apricus Biosciences (APRI) and Novartis (NVS)
www.americanbankingnews.com - February 22 at 5:10 AM |
 | Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
www.zacks.com - February 21 at 8:54 AM |
| What's Next For Apricus Biosciences' Vitaros?
finance.yahoo.com - February 20 at 5:20 PM |
| Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 19 at 8:28 AM |
| Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™ - GlobeNewswire (press release)
globenewswire.com - February 18 at 8:01 AM |
 | Mid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet - Benzinga
www.benzinga.com - February 18 at 8:01 AM |
| Shares of Apricus tank after FDA declines to OK erectile dysfunction cream
www.reuters.com - February 17 at 8:09 AM |
| Apricus Biosciences (APRI) Receives CRL from FDA for Vitaros
www.streetinsider.com - February 16 at 5:22 PM |
Apricus Biosciences (NASDAQ:APRI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Apricus Biosciences (NASDAQ:APRI) Income Statement, Balance Sheet and Cash Flow Statement
Apricus Biosciences (NASDAQ APRI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
